RE:RE:RE:RE:us The association with the Li Ka-Shing Knowledge Institute done to ensure continuity, to bring PDT mainstream. It's obvious when you re-read the news release of April 2021.
And we have a deep-pocket investor in the Li Ka-Shing group that happens to also have a pharma. So I think TLT has planned its future so execution and valuation can both be optimized and not derailed.
This TLD-1433 molecule has everything the FDA wants to see in a drug. Everything!
6 key attributes impossible for the FDA and big pharmas to pass over:
- the impressive safety track record of TLD-1433 (QOL - Quality of Life),
- the high complete response (CR%)
- the high durable response (DR%)
- the low number of treatments
- the wider accessibility of the drug (non-discrimination among patients (i.e. not scanning for a specific genetic profiles, so making this drug available to a much larger pool of patients, when compared to Keytruda for example))
- the low number of exclusion criterias